Simvastatin alleviates ConA-induced autoimmune hepatitis by inhibiting CD4+T cell activation via calcium-NFATC3 pathway

ABSTRACT: The mevalonate pathway plays a crucial role in various immune disease and Hmgcr is the key enzyme of this pathway. In addition, simvastatin, as an inhibitor of Hmgcr , also exhibits therapeutic potential for acute liver injury such as APAP-induced toxicity and hepatic ischemia-reperfusion injury (HIRI). However,its effect in ConA-induced acute liver injury remains unclear.

ORGANISM(S): Mus musculus

PROVIDER: GSE301394 | GEO | 2026/02/18

REPOSITORIES: GEO